This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: K74.3 | Special Copayment Reduction: V174 |
| B. Synonyms | Primary biliary cirrhosis | Primary biliary cholangitis |
| C. Adult onset | Likelihood of first onset in adulthood: very high — PBC occurs overwhelmingly in women in their 40s–60s, and onset before age 40 is rare. Occurrence in children is very rare, and the mean age at diagnosis is about 50–55 years. |
| 1. History | 1851 first described by Addison-Gull → 1950 named 'primary biliary cirrhosis' → 1960s AMA discovered → 1991 UDCA clinical trials → 2016 OCA approved, name changed (PBC). |
| 2. Causes | Autoimmune. Antimitochondrial antibodies (AMA-M2, anti-PDC-E2) mediate destruction of small bile duct epithelium. HLA-DRB1*08, IL-12 pathway genes. Environmental factors: urinary tract infection, exposure to toxic substances. |
| 3. Genetics | Associated with HLA-DRB1*08:01, *11. Non-HLA genes IL-12A·IL-12RB2·CTLA4·STAT4. Monozygotic twin concordance 63%. First-degree relative risk about 50-fold. X chromosome monosomy frequent. |
| 4. General epidemiology | Prevalence 20–40/100,000. Female:male = 9–10:1. Onset in 40s–60s. High incidence in Western Europe·North America. Increasing trend in Korea. Special Copayment Reduction V174. |
| 5. Pathophysiology | AMA-M2 → T-cell attack on bile duct epithelium → nonsuppurative destructive cholangitis → loss of small bile ducts → cholestasis → liver fibrosis → cirrhosis. |
| 6. Symptoms | Asymptomatic ALP elevation (diagnosis) → fatigue (70–80%, most common) → pruritus (50–70%) → jaundice (advanced stage). Osteoporosis, hyperlipidemia, and Sjögren syndrome frequently coexist. |
| 7. Signs | ALP·GGT elevation, IgM elevation, AMA-M2 positive (sensitivity 90–95%). Liver biopsy: nonsuppurative destructive cholangitis, granulomas, bile duct loss. In cirrhosis, jaundice·ascites·esophageal varices. |
| 8. Screening | Female patients with unexplained ALP elevation: AMA test. Regular ALP/AMA checks in patients with Sjögren·rheumatoid·autoimmune thyroid disease. Regular follow-up if there is a family history. |
| 9. Diagnosis | Two or more of: AMA positive + cholestatic liver enzyme elevation + liver biopsy (nonsuppurative bile duct destruction). AMA negative: anti-sp100·anti-gp210 ANA. Differentiate from AIH overlap syndrome. |
| 10. Treatment | UDCA 13–15 mg/kg/day (first line). Nonresponders: add OCA or bezafibrate. Pruritus: cholestyramine→rifampin→naltrexone. End-stage cirrhosis: liver transplantation. |
| 11. Prognosis | Survival of UDCA responders similar to the general population. Nonresponders at risk of progression to cirrhosis. Globe score predicts prognosis. Hepatocellular carcinoma risk increased about 4–18-fold. |
| 12. Prevention | No specific prevention. Early start of UDCA. Osteoporosis prevention (calcium·vitamin D). Regular endoscopy (surveillance of esophageal varices). Active screening in patients with coexisting autoimmune disease. |
| 13. References | Lindor KD et al. Primary biliary cholangitis. Hepatology. 2019 … and 9 other references |
The history of Primary Biliary Cholangitis (PBC) begins in 1851, when Thomas Addison and William Gull of England first described the clinical case of a female patient with jaundice, pruritus of the skin, and cutaneous xanthomas. At that time the etiology was completely unknown, but from the late 19th century cholestasis was confirmed as a main feature. In the early 20th century, several investigators reported cases characterized by chronic intrahepatic cholestasis and progressive liver fibrosis, and in 1950 Ahrens et al. in the United States named it 'primary biliary cirrhosis (PBC)'.
The key turning point in elucidating the etiology came in the 1960s. When Walker, Sherlock, and others discovered antimitochondrial antibody (AMA) in the serum of PBC patients, it was strongly suggested that the disease has an autoimmune mechanism. In the 1980s, the main target antigen of AMA was found to be the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) in the inner mitochondrial membrane. Identification of this antigen contributed decisively to establishing the standard diagnostic test for PBC.
The turning point in treatment history began in 1987 when Poupon et al. applied ursodeoxycholic acid (UDCA) to PBC. Subsequently, numerous randomized controlled trials and meta-analyses confirmed that UDCA is effective in improving biochemical markers, inhibiting progression of liver fibrosis, and improving long-term survival; it received US FDA approval in 1997 and has been used as the foundation of PBC treatment to this day.
In 2016, by consensus of international societies, the name was changed to 'Primary Biliary Cholangitis (PBC)'. The reasons for the change were that not all patients are in a cirrhotic state, and that the term 'cirrhosis' could give patients excessive fear and stigma about prognosis. In the same year, obeticholic acid (OCA), an FXR (farnesoid X receptor) agonist, received FDA approval for patients with an insufficient response to UDCA, expanding PBC treatment options. In 2024, bezafibrate was approved in Europe as add-on treatment to UDCA. In Korea it is also managed as a disease eligible for rare disease Special Copayment Reduction (V174).
The cause of PBC has not been fully elucidated; current understanding is represented by a multifactorial model in which an autoimmune response is triggered by environmental factors in genetically predisposed individuals. Although an autoimmune mechanism is established as the main etiology, the triggers of the initial breakdown of self-tolerance are not yet clear.
Antimitochondrial antibody (AMA) and autoimmune mechanism: AMA-M2 (anti-PDC-E2) positivity is found in 90–95% of PBC patients. PDC-E2 is a protein of the inner mitochondrial membrane that normally exists inside the cell, but in PBC it is abnormally expressed on the cell surface of biliary epithelial cells and becomes the target of autoimmune attack. The core lesion is destruction of the bile duct epithelium by CD4+ and CD8+ T lymphocytes infiltrating intensively around the small bile ducts.
Genetic predisposition: HLA-DRB1*08:01 (mainly Western Europe) and DRB1*11 (Italy, Japan) are associated with increased PBC risk. As non-HLA genes, variants in immune regulatory genes such as IL-12A, IL-12RB2 (IL-12/IL-23 signaling pathway), CTLA4 (inhibition of T-cell activation), STAT4 (Th1 differentiation), and IRF5 have been identified through GWAS. These genes are involved in pathways that regulate the initiation and amplification of autoimmune responses.
Environmental factors: An association between recurrent urinary tract infection (especially Escherichia coli) and the development of PBC has been reported in epidemiological studies. According to the molecular mimicry hypothesis, an immune response to bacterial PDC-E2-like antigens may induce cross-reactive autoimmunity against self PDC-E2. Cosmetic ingredients (lipoic acid derivatives, lipstick ingredients), halogenated hydrocarbons, and smoking have also been proposed as risk factors for PBC.
X chromosome aneuploidy: The frequency of X chromosome monosomy in lymphocytes of female PBC patients is markedly higher than in healthy controls. Abnormal haploid expression of X-linked immune regulatory genes (FOXP3, CD40L, etc.) is a candidate mechanism explaining the extreme female bias of PBC (9–10:1).
Primary biliary cholangitis has a multifactorial genetic architecture, and the monozygotic twin concordance rate of about 63% suggests relatively high heritability among autoimmune liver diseases. In first-degree relatives (especially mothers and daughters, sisters), the risk of PBC is about 50 times higher than in the general population. Familial PBC (family clustering) is observed in about 5–7% of all cases.
HLA gene associations: Because HLA genes play a key role in antigen presentation and T-cell selection, they are strongly associated with autoimmune diseases. In PBC, HLA-DRB1*08:01 (Northern European and North American patients) and DRB1*11:01 (Italian, Japanese patients) are reported as risk alleles, and HLA-DRB1*03:01 as a protective allele. There are studies suggesting that HLA genotype may also be associated with disease phenotype (UDCA response, rate of progression).
Non-HLA gene loci: More than 30 PBC susceptibility loci have been identified through large-scale GWAS (Genome-Wide Association Study). The most notable are IL-12A (5q31.1) and IL-12RB2 (1p31.3), key components of the IL-12-mediated Th1 immune response. CTLA4 (2q33.2) and TNFSF15 are involved in regulating autoimmune responses. Interestingly, many genes associated with PBC are shared with other autoimmune diseases such as Crohn disease, lupus, and rheumatoid arthritis. This suggests that autoimmune diseases share common pathways of immune dysregulation.
PBC is by definition not a hereditary liver disease, and it is not necessarily inherited by the children of PBC patients. However, because risk increases when there is a family history, it is reasonable to recommend regular ALP·AMA testing for first-degree relatives (especially middle-aged women). Currently, no gene therapy or gene-based prevention strategy for PBC is clinically established.
Primary biliary cholangitis is a rare autoimmune liver disease with the highest prevalence in Western Europe and North America. Prevalence is reported at about 27–40 per 100,000 population in the UK and about 20–35 in the United States. The annual incidence is about 2–5 per 100,000 population. Global prevalence estimates continue to rise, largely owing to improved diagnostic awareness, widespread AMA testing, and population aging.
Sex distribution: PBC shows the most pronounced female bias of all autoimmune diseases, with a female:male ratio of about 9–10:1. Male PBC is relatively rare, but men are often at a more advanced stage at diagnosis and tend to have a relatively poorer prognosis owing to a poor UDCA response.
Age distribution: Onset is mainly in the 40s–60s, and onset before age 40 is rare. The mean age at diagnosis is about 50–55 years. When diagnosed at an older age, the disease is likely already at an advanced stage.
Epidemiology in Asia·Korea: Prevalence in Asia is reported to be lower than in the West, but in Japan a prevalence of about 10–15 per 100,000 population has been confirmed. Accurate epidemiological data for Korea are limited, but the number of patients registered for rare disease Special Copayment Reduction (V174) is increasing. In Korean PBC patients, female predominance and coexisting autoimmune diseases are also observed, similar to the West.
Coexisting autoimmune diseases: About 70–80% of PBC patients have another autoimmune disease. The most common are Sjögren syndrome (about 30–50%), autoimmune thyroid disease (about 15–20%), Raynaud phenomenon (about 15%), and rheumatoid arthritis. The overlap of systemic sclerosis (CREST syndrome) and PBC is also well known.
The core pathophysiology of PBC is a selective autoimmune attack on the biliary epithelial cells (cholangiocytes) of the interlobular and septal bile ducts (diameter <100 μm).
Targeting of biliary epithelial cells: Normally PDC-E2 is located in the inner mitochondrial membrane and is expressed only within the cytoplasm. In PBC, during cell injury or apoptosis, PDC-E2 is abnormally expressed on the surface of biliary epithelial cells (apotope formation) and becomes a target of AMA and T cells. Why this process is particularly prominent in small bile duct epithelial cells has not been fully elucidated, but it has been hypothesized that the low glutathione content of the small bile duct epithelium makes it more vulnerable to oxidative stress.
T-cell-mediated bile duct destruction: CD4+ Th1 cells secrete IFN-γ and IL-12 to induce an inflammatory response, and CD8+ cytotoxic T cells exert direct cytotoxicity on biliary epithelial cells. Non-suppurative destructive cholangitis forms around the bile ducts, and granulomas are observed around the portal tracts. If this chronic inflammation and bile duct destruction persist, the small bile ducts are progressively lost.
Cholestasis and secondary injury: With the loss of small bile ducts, intrahepatic drainage of bile is impaired and cholestasis develops. Hydrophobic bile acids (toxic bile acids) accumulate in the liver, causing direct hepatocyte toxicity, oxidative stress, and secondary inflammation. Persistent hepatocyte injury due to cholestasis activates hepatic stellate cells, causing excessive collagen deposition and liver fibrosis. When this process repeats, it progresses to cirrhosis and portal hypertension.
Mechanisms of action of UDCA and OCA: UDCA converts the hydrophobic bile acid pool to a hydrophilic one and reduces cholestasis through cytoprotection of the bile duct epithelium, immunomodulation, and partial activation of FXR signaling. OCA (obeticholic acid) is a potent FXR agonist that suppresses bile acid synthesis and increases ileal FGF19 secretion, providing feedback inhibition of intrahepatic bile acid synthesis.
The clinical symptoms of primary biliary cholangitis vary with the disease stage (early vs. advanced). Today, many patients are discovered incidentally through elevated ALP or GGT on blood tests before symptoms appear.
Fatigue is the most common symptom of PBC, reported in about 70–80% of all patients. Central fatigue (reduced motivation, cognitive impairment), peripheral muscle fatigue, and sleep disturbance appear in combination. The degree of fatigue is not necessarily proportional to liver function or degree of fibrosis, and it often persists despite treatment. Abnormal serotonin signaling, autonomic dysfunction, daytime sleepiness, and abnormal cortisol response are being studied as mechanisms of fatigue.
Pruritus is the second most common major symptom, occurring in about 50–70% of patients. It tends to worsen at night and to start at the distal extremities. Besides bile acids, lysophosphatidic acid (LPA), opioid substances, and histamine are being studied as mediators of pruritus. Severe pruritus greatly reduces quality of life, and treatment-refractory pruritus can be an indication for liver transplantation.
Jaundice does not appear in the early stage; it develops at a stage when loss of small bile ducts has progressed considerably and bile excretion is reduced. The appearance of jaundice is an important clinical sign suggesting progression to cirrhosis, and elevated bilirubin is a poor prognostic factor.
Osteoporosis: Osteoporosis coexists in about 30–50% of PBC patients. Malabsorption of fat-soluble vitamins (vitamin D) due to cholestasis, reduced calcium absorption, and chronic inflammation cause decreased bone density. Because the risk of pathological fracture increases, regular bone density testing and preventive treatment are needed.
Other symptoms: Hyperlipidemia (xanthoma formation), symptoms of Sjögren syndrome (dry eyes, dry mouth), Raynaud phenomenon, and symptoms of thyroid dysfunction may coexist.
Serum biochemical findings: Marked elevation of ALP and GGT (disproportionately high compared with AST and ALT) is the typical pattern of PBC. This is a cholestatic liver enzyme pattern. Marked elevation of serum IgM (relatively specific for PBC) is observed. Total bilirubin, albumin, and PT/INR become abnormal at advanced stages. Elevated bilirubin is the strongest poor prognostic factor.
Serum autoantibodies: AMA-M2 (anti-PDC-E2) positivity, with a sensitivity of 90–95% and specificity of 95–98%, is highly specific for PBC. Testing is performed by ELISA or indirect immunofluorescence (IIF). In AMA-negative cases (about 5–10% of all), specific subtypes of antinuclear antibody (ANA)—anti-sp100 (anti-nuclear dot antibody) and anti-gp210 (anti-nuclear envelope antibody)—are alternative markers specific for PBC. Anti-sp100 has a specificity of about 97% and anti-gp210 about 99%, which are very high.
Liver biopsy findings: Disease progression is assessed using the Ludwig staging classification (Stage I: inflammation confined to the periductal area; Stage II: extension of periductal fibrosis; Stage III: bridging fibrosis; Stage IV: cirrhosis). The typical finding in stage I, the 'florid duct lesion'—dense lymphocytic infiltration destroying the bile duct epithelium with surrounding granuloma formation—is the most specific.
Liver elastography: As a noninvasive alternative to liver biopsy, it measures liver stiffness to estimate the stage of fibrosis. It is useful for monitoring PBC progression.
There is no screening program for PBC in the general population. However, early screening in specific high-risk groups is important for reducing diagnostic delay and bringing forward the start of treatment.
Unexplained cholestatic liver enzyme abnormalities: In women in their 40s–60s with ALP and GGT markedly elevated relative to ALT, extrahepatic biliary obstruction (gallstones, tumors) is first excluded by abdominal ultrasound, and then serum AMA-M2 testing is performed. If AMA is negative, proceed to anti-sp100 and anti-gp210 testing.
Patients with coexisting autoimmune diseases: Because PBC is likely to coexist in patients with Sjögren syndrome, rheumatoid arthritis, autoimmune thyroid disease, and CREST syndrome (limited systemic sclerosis), liver function follow-up including ALP and AMA testing is recommended at the initial visit and every 1–2 years.
When there is a family history: Regular ALP·AMA testing from the 40s onward is recommended for women whose mother or sister has PBC. When there is a family history, testing from an earlier age and more often (annually) may be reasonable.
According to EASL and AASLD guidelines, the diagnosis of PBC is confirmed when two or more of the following three criteria are met: ① cholestatic biochemical abnormality (ALP ≥ 1.5 × ULN), ② AMA positive (titer ≥1:40 or M2 subtype), ③ nonsuppurative destructive cholangitis and bile duct loss on liver biopsy.
AMA testing protocol: When an antimitochondrial pattern is identified on indirect immunofluorescence (IIF), the M2 subtype (anti-PDC-E2) is confirmed by ELISA. Some institutions perform ELISA directly as the first-line test. If AMA is negative, anti-sp100 and anti-gp210 are additionally tested. Diagnosis is also possible with ANA positivity (anti-sp100 or anti-gp210) + typical clinical/biochemical findings.
Liver biopsy: With typical AMA positivity + typical biochemical findings (criteria ① + ② met), a clinical diagnosis is possible without biopsy. Biopsy is performed for atypical cases (young men, abrupt ALT elevation, AMA negative), for differentiating AIH-PBC overlap syndrome, and when accurate staging is needed.
AIH-PBC overlap syndrome: A condition in which features of PBC and autoimmune hepatitis (AIH) appear at the same time. Overlap syndrome is diagnosed when AIH features (marked ALT elevation, ANA/SMA positivity, marked IgG elevation, interface hepatitis on histology) coexist with PBC features, and combination therapy of UDCA + steroids (azathioprine may be added) is applied.
Assessment of treatment response (Paris II criteria): After 1 year of UDCA treatment, patients with ALP ≤3 × ULN AND AST ≤2 × ULN AND total bilirubin ≤1 mg/dL are classified as adequate UDCA responders. If these criteria are not met, adding OCA or bezafibrate is considered.
The core goals of PBC treatment are suppression of bile duct destruction, delay of liver fibrosis progression, improvement of cholestasis, and improvement of quality of life.
Ursodeoxycholic acid (UDCA): 13–15 mg/kg/day (divided into 2 or 3 doses daily) is the standard treatment. Mechanisms: ① replacement of hydrophobic bile acids with hydrophilic UDCA to reduce hepatocyte toxicity, ② protection of the bile duct epithelium (cytoprotection), ③ immunomodulation (reduced HLA class I expression, NF-κB inhibition), ④ suppression of bile acid synthesis through partial FXR activation. Long-term UDCA treatment improves biochemical markers, inhibits progression of liver fibrosis, and lowers the risk of liver transplantation and death. It is well tolerated and relatively safe even during pregnancy.
Obeticholic acid (OCA): Approved as add-on treatment when there is no adequate response after UDCA treatment (Paris II criteria not met). Start at 5 mg/day and increase to 10 mg/day after 6 months. In the phase 3 POISE trial, adding OCA significantly reduced ALP and bilirubin. Main adverse effect: worsening of pruritus. In patients with cirrhosis (Child-Pugh B/C), caution is needed because of the risk of worsening portal hypertension.
Bezafibrate: A PPAR-α agonist that suppresses bile acid synthesis. In the phase 3 BEZURSO trial, UDCA + bezafibrate was significantly superior to UDCA alone for ALP normalization and improvement of pruritus. In 2024 it was approved in Europe for PBC patients with an insufficient response to UDCA.
Treatment of pruritus: Step 1: cholestyramine (bile acid-binding resin, 4–16 g per day); Step 2: rifampin (induces bile acid metabolism through PXR activation, 150–300 mg/day, hepatotoxicity monitoring required); Step 3: naltrexone (opioid receptor antagonist), sertraline (serotonin reuptake inhibitor); Step 4: if refractory to treatment, plasma exchange, nasobiliary drainage, liver transplantation.
Liver transplantation: Considered when MELD ≥15, bilirubin ≥6 mg/dL, treatment-refractory pruritus, recurrent bacterial cholangitis, or complicating hepatocellular carcinoma is present. The 5-year survival after transplantation is excellent at about 80–85%, but PBC recurs in about 10–30%, and UDCA treatment is maintained after transplantation.
The prognosis of primary biliary cholangitis depends greatly on response to UDCA treatment. Large studies have reported that life expectancy in adequate UDCA responders (meeting Paris II criteria) is nearly the same as in the general population.
Prognostic tools: The Globe score (based on age at diagnosis, bilirubin, ALP, albumin, platelets; values after 1 year of UDCA) and the UK-PBC score (predicting 5- and 10-year risk of liver transplantation/death) are used in clinical practice as standardized prognostic tools. Elevated bilirubin is the single strongest poor prognostic factor.
Risk factors for progression: Nonresponse to UDCA treatment (Paris II not met), male sex, advanced stage at diagnosis (Ludwig III–IV), high bilirubin, low albumin, thrombocytopenia, and coexisting AIH are poor prognostic factors.
Liver cancer risk: In PBC patients, the risk of hepatocellular carcinoma (HCC) is increased about 4–18-fold compared with the general population. The risk is especially high in male PBC, advanced cirrhosis, and low platelets. In PBC patients with cirrhosis, HCC surveillance with ultrasound + serum AFP every 6 months is recommended.
Complications of portal hypertension: With progression to cirrhosis, esophageal varices, ascites, spontaneous bacterial peritonitis, and hepatic encephalopathy develop. Esophageal varices are assessed by endoscopy at the initial visit and during follow-up, and prophylactic beta-blockers or endoscopic variceal ligation are used.
There is no specific method to prevent the development of PBC. However, starting UDCA early after diagnosis and actively managing complications is the most effective strategy for improving long-term prognosis.
Early initiation and continuous use of UDCA are most important for slowing bile duct destruction and progression of liver fibrosis. To prevent osteoporosis, calcium (1,000–1,500 mg/day) and vitamin D (800–1,000 IU/day) are supplemented, and bone density is regularly assessed by DEXA. When osteoporosis is diagnosed, bisphosphonate treatment is given, with intravenous formulations preferred over oral bisphosphonates because of the risk of esophagitis.
Monitoring for deficiency of fat-soluble vitamins (A, D, E, K) and supplementation when needed are required. When Sjögren syndrome coexists, tooth loss is prevented with oral care (artificial saliva, oral rinsing) and regular dental checkups. At the cirrhosis stage, regular endoscopy (surveillance of esophageal varices) and ultrasound (surveillance for hepatocellular carcinoma) are essential. Patients awaiting liver transplantation keep their vaccinations (influenza, pneumococcus, hepatitis B, HAV) up to date.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. DOI: 10.1002/hep.30145. PMID: 30070375.
Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis (POISE). N Engl J Med. 2016;375(7):631-643. DOI: 10.1056/NEJMoa1509840. PMID: 27532829.
Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis (BEZURSO). N Engl J Med. 2018;378(23):2171-2181. DOI: 10.1056/NEJMoa1714519. PMID: 29874528.
Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324(22):1548-1554. DOI: 10.1056/NEJM199105303242204. PMID: 1674105.
Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360(24):2544-2555. DOI: 10.1056/NEJMoa0810440. PMID: 19458352.
Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis (Global PBC study). Gastroenterology. 2014;147(6):1338-1349. DOI: 10.1053/j.gastro.2014.08.029. PMID: 25160979.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172. DOI: 10.1016/j.jhep.2017.03.022. PMID: 28427765.
Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology. 2001;33(1):16-21. DOI: 10.1053/jhep.2001.21165. PMID: 11124819.
Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194-1202. DOI: 10.1002/hep.20907. PMID: 16250040.
Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63(3):930-950. DOI: 10.1002/hep.28393. PMID: 26223498.